HEPLISAV-B

Drug Dynavax Technologies Corporation
Total Payments
$281,507
Transactions
44
Doctors
14
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2018 $281,507 44 14

Payments by Nature

Nature of Payment Amount Transactions Share
Current or prospective ownership or investment interest $156,767 1 55.7%
Consulting Fee $116,268 23 41.3%
Travel and Lodging $7,850 9 2.8%
Food and Beverage $621.95 11 0.2%

Top Doctors Receiving Payments for HEPLISAV-B

Doctor Specialty Location Total Records
, MD Rheumatology La Jolla, CA $180,648 9
Carol Brosgart Berkeley, CA $77,977 17
, MD Clinical & Laboratory Immunology Doylestown, PA $10,000 1
, M.D Gastroenterology Stanford, CA $4,311 2
, MD Specialist Cresskill, NJ $2,250 1
, MD Medical Oncology Wyoming, MI $1,800 1
, M.D Contractor Bethesda, MD $1,400 1
Andrew Bernstein Pediatrics Bel Air, MD $1,305 3
, MD, MPH Internal Medicine Poughkeepsie, NY $808.29 3
, MD Internal Medicine Charlotte, NC $600.00 1
, M.D Hospitalist Greenville, NC $115.42 1
, M.D Infectious Disease Greenville, NC $115.41 1
, MD Infectious Disease Greenville, NC $115.41 1
, MD Internal Medicine New York, NY $46.83 1
Benson Yu Fairfax, VA $13.62 1

About HEPLISAV-B

HEPLISAV-B is a drug associated with $281,507 in payments to 14 healthcare providers, recorded across 44 transactions in the CMS Open Payments database. The primary manufacturer is Dynavax Technologies Corporation.

Payment data is available from 2018 to 2018. In 2018, $281,507 was paid across 44 transactions to 14 doctors.

The most common payment nature for HEPLISAV-B is "Current or prospective ownership or investment interest" ($156,767, 55.7% of total).